Latest From Clorox Co.
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
FitLife direct-to-consumer, online sales fuel quarter; AXIM Wellness launching CBD gum; Canadian firm acquiring PA cannabis cultivator; Clorox' lifestyle division flat in latest quarter despite strong sales of NutraNext supplements; and New Age delays rolling beverage line on confusing FDA regulation messaging.
P&G, Church & Dwight and Clorox executives say firms are looking to add brands to portfolios. P&G's developing assets through a brand creation project; C&D seeks top brands, largely in non-US markets; and Clorox looks for opportunities in select ‘spaces’ in US health, wellness and personal care.
A “sober” assessment of e.l.f.’s strategy and governance is “clearly warranted and long overdue,” says Marathon Partners founder and Managing Partner Mario Cibelli in a letter to the company’s board. E.l.f.’s share price has been on a steady decline as sales growth has slowed, with a roughly flat performance reported by the firm in November for the first three quarters of fiscal 2018.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Clorox Co.
- Senior Management
- Contact Info
Phone: (415) 271-7000
Oakland, CA 94612
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.